UK-based contract research organisation (CRO) Chiltern International has announced a partnership with Charles River Laboratories under which Chiltern’s Early Phase business will team up with Charles River to conduct and support early-phase radiolabelled studies.
The clinical aspects of these studies will be undertaken by Chiltern Early Phase at its hospital-based clinical pharmacology unit in Dundee, Scotland. Charles River runs a Metabolism and Pharmacokinetics group in Edinburgh, Scotland, which has been conducting radiolabelled trials in humans for more than 20 years.
In the UK, Chiltern has integrated early-phase units in Slough and Dundee. The latter facility in Ninewells Hospital was acquired with Phase I specialist Drug Development Solutions (DDS) in February 2008.
According to Chiltern, Charles River is known worldwide for its experience with clinical studies involving radiolabelled investigational products. The US-based CRO’s expertise includes submission and review procedures for radiolabelled studies in humans, such as dosimetry calculations and filing with the UK Department of Health’s Administration of Radioactive Substances Advisory Committee.
This latest collaboration with Charles River brings complementary strengths that “add a new dimension to the full CRO services that Chiltern already provides, continuing to demonstrate our commitment to providing our clients with the highest standard of quality and expertise”, said chief executive officer Glenn Kerkhof.
